Last updated on July 2019

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)


Brief description of study

The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period. It is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.

Detailed Study Description

This study will have a main 24-week treatment period and a 28-week extension period of treatment. Participants at selected sites and countries who complete the main and extension study periods may consent to participate in an observational, 3-month, Off-treatment Durability Study Period.

Clinical Study Identifier: NCT03449147

Find a site near you

Start Over

Abraham Research, PLLC ( Site 0107)

Fort Mitchell, KY United States
  Connect »

Pulmonix LLC ( Site 0028)

Greensboro, NC United States
  Connect »

MediTrial s.r.o ( Site 0702)

Jindrichuv Hradec III, Czechia
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.